Sixfold Bioscience

About Sixfold Bioscience

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

<problem> Effective delivery of RNA therapies to target cells remains a significant challenge, limiting their therapeutic potential and patient outcomes. Traditional delivery methods often struggle with stability, specificity, and efficient cellular uptake. </problem> <solution> Sixfold Bioscience has developed Mergo®, an AI-driven platform designed to enhance the delivery of RNA therapies. Mergo® addresses the limitations of existing delivery mechanisms by improving the stability, targeting, and cellular uptake of RNA molecules. This technology aims to increase the efficacy of RNA therapeutics, leading to better patient outcomes. By leveraging AI, Mergo® optimizes the delivery process, ensuring that RNA therapies reach their intended targets with greater precision and efficiency. </solution> <features> - AI-driven platform for optimizing RNA delivery mechanisms - Enhanced stability of RNA molecules during transit - Improved targeting of specific cells and tissues - Increased cellular uptake of RNA therapies </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving RNA-based therapeutics. </target_audience>

What does Sixfold Bioscience do?

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

Where is Sixfold Bioscience located?

Sixfold Bioscience is based in London, United Kingdom.

When was Sixfold Bioscience founded?

Sixfold Bioscience was founded in 2018.

How much funding has Sixfold Bioscience raised?

Sixfold Bioscience has raised 10620000.

Location
London, United Kingdom
Founded
2018
Funding
10620000
Employees
15 employees
Major Investors
Innovate UK, Y Combinator, Bossa Invest, European Commission, MedCity News

Find Investable Startups and Competitors

Search thousands of startups using natural language

Sixfold Bioscience

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Sixfold Bioscience develops Mergo®, a platform that utilizes AI to enhance the delivery mechanisms for RNA therapies. This technology addresses the challenge of effectively transporting RNA molecules to target cells, improving therapeutic efficacy and patient outcomes.

sixfold.bio5K+
cb
Crunchbase
Founded 2018London, United Kingdom

Funding

$

Estimated Funding

$10M+

Major Investors

Innovate UK, Y Combinator, Bossa Invest, European Commission, MedCity News

Team (15+)

No team information available.

Company Description

Problem

Effective delivery of RNA therapies to target cells remains a significant challenge, limiting their therapeutic potential and patient outcomes. Traditional delivery methods often struggle with stability, specificity, and efficient cellular uptake.

Solution

Sixfold Bioscience has developed Mergo®, an AI-driven platform designed to enhance the delivery of RNA therapies. Mergo® addresses the limitations of existing delivery mechanisms by improving the stability, targeting, and cellular uptake of RNA molecules. This technology aims to increase the efficacy of RNA therapeutics, leading to better patient outcomes. By leveraging AI, Mergo® optimizes the delivery process, ensuring that RNA therapies reach their intended targets with greater precision and efficiency.

Features

AI-driven platform for optimizing RNA delivery mechanisms

Enhanced stability of RNA molecules during transit

Improved targeting of specific cells and tissues

Increased cellular uptake of RNA therapies

Target Audience

The primary target audience includes pharmaceutical companies and research institutions focused on developing and improving RNA-based therapeutics.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.